Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 4,780 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Cancers Clear all

Conditions: Lung Cancer, Gastric Cancer, Pancreatic Cancer
Interventions: Testing an interactive technology in a diverse health literary population; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
Interventions: XmAb®23104, Yervoy® (ipilimumab); Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 18
States / cities: San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more

Conditions: Neoplasms
Interventions: CC-90011, Nivolumab; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 8
States / cities: Indianapolis, Indiana • New York, New York • Canton, Ohio + 5 more

Conditions: Multiple Myeloma in Relapse, Multiple Myeloma
Interventions: SOM230, Bortezomib, Dexamethasone; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Ewing Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Ewing's Tumor Recurrent, Rare Diseases, Sarcoma, Neoplasms, Connective and Soft Tissue, Neoplasms by Histologic Type, Neoplasms, Bone Tissue, Neoplasms, Connective Tissue, Sarcoma, Ewing, Neoplasms
Interventions: Vigil, Irinotecan, Temozolomide; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 15
States / cities: Little Rock, Arkansas • Los Angeles, California • Jacksonville, Florida + 12 more

Conditions: Neuroendocrine Prostate Cancer (NEPC), Metastatic Prostate Adenocarcinoma, Prostate Cancer
Interventions: Ifinatamab Deruxtecan, Positron Emission Tomography (PET)/Computerized Tomography (CT), Computerized Tomography (CT)/ Magnetic Resonance Imaging (MRI), Bone Scan, Blood Specimen Collection; Drug · Procedure
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Leukemia, Acute Lymphoblastic, Multiple Myeloma, Myelofibrosis
Interventions: Molecular diagnostic testing; Genetic
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: lenalidomide, melphalan, prednisone; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: B Cell Lymphomas, Multiple Myeloma, Solid Tumor, HER-2 Protein Overexpression
Interventions: ACTR T Cell Product; Other
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 16
States / cities: Gilbert, Arizona • Phoenix, Arizona • New Haven, Connecticut + 13 more

Conditions: Chemotherapy-induced Peripheral Neuropathy
Interventions: thrombomodulin alfa, Placebo; Drug
Lead sponsor: Asahi Kasei Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 18
States / cities: Beverly Hills, California • Los Angeles, California • Norwich, Connecticut + 15 more

Conditions: Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
Interventions: MIK665; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Cancer, Solid Tumors, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Interventions: FN-1501; Drug
Lead sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Fairway, Kansas • Detroit, Michigan

Conditions: Pancreatic Cancer
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis
Interventions: KITE-363, Fludarabine, Cyclophosphamide; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Newport Beach, California • Palo Alto, California • New York, New York + 2 more

Conditions: Pulmonary Nodules
Interventions: Linear EBUS first, Robotic-assisted bronchoscopy first; Diagnostic Test
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 5
States / cities: Sacramento, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Renal Cell Carcinoma
Interventions: Bevacizumab, Ixabepilone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Bethesda, Maryland • Charleston, South Carolina

Conditions: Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia, CML, Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Leukemia
Interventions: Itacitinib; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 60 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lung Cancer, Adjuvant, Post-surgical, EGFR, Exon 20, Early Stage Lung Cancer, Uncommon EGFR Mutations, NSCLC, Early Stage
Interventions: TAS6417, Zipalertinib Matching-placebo; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 30
States / cities: Anchorage, Alaska • Duarte, California • Irvine, California + 26 more

Conditions: Non-small Cell Lung Cancer
Interventions: NRX194204; Drug
Lead sponsor: NuRx Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Fountain Valley, California • La Jolla, California • Los Angeles, California + 3 more

Conditions: Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
Interventions: Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX, TAS 102, Bevacizumab, Gemcitabine Combined With Cisplatin, NALIRIFOX; Drug
Lead sponsor: Phanes Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 11
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 8 more

Conditions: Prostate Cancer
Interventions: Whole-food, Plant-Based Diet, General Nutritional Counseling; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 45 Years to 99 Years · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: Baltimore, Maryland • New York, New York

Conditions: Prostatic Neoplasms
Interventions: 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 469 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 20
States / cities: Denver, Colorado • Gainesville, Florida • New Orleans, Louisiana + 13 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Everolimus, Everolimus Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 742 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 34
States / cities: Chandler, Arizona • Fayetteville, Arkansas • La Jolla, California + 29 more

Conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Belantamab Mafodotin, Daratumumab, Dexamethasone, Lenalidomide, Quality-of-Life Assessment, Biospecimen Collection, Skeletal Survey X-Ray, Low Dose Computed Tomography of the Whole Body, Bone Marrow Aspiration, Bone Marrow Biopsy; Biological · Drug · Other + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Effect of Multi-Media Tool on Enrollment in Oncology Clinical Trials

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide

Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer

iCare for Cancer Patients

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product

Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients

Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

Registry for Pancreatic Cancer

Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

The SEQUENCE Trial

Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer

Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma